全膝关节置换术中髌骨置换:英国大型多中心随机对照试验20年临床与经济结果
该多中心随机对照试验纳入1715例初次全膝关节置换患者,随机分为髌骨置换组与不置换组,随访20年。
要点
- 20年随访OKS差异无统计学意义,但多项临床终点数值上偏向髌骨置换。
- 髌骨置换组QALYs显著更高,但假设死亡率无差异的敏感性分析中差异变小且不显著。
- 20年总医疗成本两组相似,髌骨置换在每QALY阈值高于£10 000时成本有效概率达99%。
核心结论
- 主要结局OKS及其他临床终点无显著差异,但临床差异倾向于支持髌骨置换,且髌骨置换组QALYs显著更高,证据权重倾向于髌骨置换为首先选择。
研究设计与样本
- pragmatisch、多中心、开放标签随机对照试验,于1999年在英国启动,采用部分析因设计,随访20年。
- 采用自动化电话服务按1:1分配,按外科医生分层,并根据患者年龄(<60岁、60-79岁、≥80岁)、性别和疾病部位进行最小化。
- 主要结局为牛津膝关节评分(OKS),采用重复测量混合效应线性回归分析并报告边际差异。
主要发现
- 20年随访时,髌骨置换组132例、不置换组110例提供结局数据,边际差异分析还包括死亡或20年数据缺失参与者的早期数据。
- 20年随访期间,OKS、SF-12、EQ-5D-3L、再入院、次要或中间手术、髌骨相关手术、重大手术及并发症的差异虽不显著,但均倾向于髌骨置换。
关键数值与推荐
- 髌骨置换在每QALY阈值高于£10 000时具有99%的成本有效概率。
临床怎么用
- 结合OKS无显著差异但QALYs显著更高及成本相似的结果,证据权重支持将髌骨置换作为初次全膝关节置换的首选方式。
局限性
- 20年随访时提供结局数据的参与者数量较少(髌骨置换组132例,不置换组110例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is conflicting evidence regarding the merits of patellar resurfacing during total knee replacement (TKR), as previous randomised controlled trials (RCTs) have been under-powered and with follow-up of ten years or less. METHODS: A pragmatic, multicentre, open-label RCT was initiated in 1999 in the UK. Within a partial-factorial design, participants were randomly allocated to receive or not receive patellar resurfacing during primary TKR and were followed up for 20 years. Adult (aged ≥18 years) patients due to have a primary TKR under the care of a collaborating surgeon were eligible. Participants were allocated (1:1) using an automated telephone service stratified by surgeon, with minimisation according to the patients' age (<60 years, 60-79 years, ≥80 years), sex, and location of d isease. The primary outcome measure was the Oxford Knee Score (OKS), analysed using repeated measures mixed-effects linear regression analysis with marginal differences reported. Secondary measures included the 12-Item Short Form Health Survey (SF-12), the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L), costs, cost-effectiveness, and subsequent knee surgery. This trial is registered with ISRCTN Registry, ISRCTN45837371. FINDINGS: Between April 8, 1999, and Jan 13, 2003, 1715 participants (955 female and 760 male; mean age 70 years [SD 8], mean BMI 29·7 kg/m2) were randomly assigned: 861 to patellar resurfacing and 854 to no resurfacing. At the 20-year follow-up, 132 participants in the patellar resurfacing group and 110 participants in the non-resurfacing group provided outcome data, although marginal differences included earlier data for participants who died or had missing 20-year data. The marginal difference in OKS over the whole 20-year follow-up was 0·76 (95% CI -0·08 to 1·59; p=0·076) in favour of patellar resurfacing. During the 20-year follow-up period, although not significant, differences in OKS, SF-12, and EQ-5D-3L, readmissions, minor or intermediate operations, patella-related operations, major operations, and complications all favoured patellar resurfacing. At 20 years, the resurfaced group accrued significantly more quality-adjusted life-years (QALYs) than the non-resurfaced group (7·295 vs 6·884; difference 0·380, 95% CI 0·061 to 0·700; p=0·020). However, QALY differences were smaller in a sensitivity analysis assuming no difference in mortality (7·209 vs 6·964; difference 0·183, 95% CI -0·034 to 0·400; p=0·10). The cost of readmissions was non-significantly lower in the resurfaced group and offset the higher cost of primary TKR; therefore, overall 20-year health-care costs per participant were similar (£10 825 vs £10 889; difference -£6, 95% CI -£721 to £708; p=0·99). INTERPRETATION: There was no significant difference in primary outcome (OKS) or other clinical endpoints. However, as clinical differences tend to support patellar resurfacing, the resurfacing group had significantly higher QALYs. There was no difference in costs over the 20-year period, and patellar resurfacing had a 99% probability of being cost-effective at any threshold above £10 000 per QALY gained. The evidence is therefore weighted towards resurfacing being the approach of first choice. FUNDING: UK National Institute for Health and Care Research Health Technology Assessment Programme.
引用
- Murray DW, Hudson J, Dakin H, et al. Patellar resurfacing in total knee replacement: 20-year clinical and economic results of a large multicentre, randomised controlled trial in the UK. Lancet. 2026. PMID: 42309116. doi:10.1016/S0140-6736(26)00652-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。